Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00092001 · ClinicalTrials.gov registry record · Phase 2
Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer
A Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
- 14
- Study locations
NCT00092001 is a Phase 2 study of Carcinoma, Non-Small Cell Lung that has completed, run by Pfizer. The registered enrollment target is 111 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (66% lower). The trial reports 14 study locations across 8 states.
The verdict
NCT00092001, a Phase 2 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to test whether SU011248 has activity and is safe in patients with metastatic non-small cell lung cancer (NSCLC) who have failed a platinum-containing regimen and docetaxel.
Conditions Studied
Interventions
- DRUG Sunitinib
Study Locations (14)
North Carolina
- Pfizer Investigational Site - Chapel Hill
- Pfizer Investigational Site - Clinton
- Pfizer Investigational Site - Goldsboro
- Pfizer Investigational Site - Pollocksville
- Pfizer Investigational Site - Wilson
Missouri
- Pfizer Investigational Site - City of Saint Peters
- Pfizer Investigational Site - St Louis
- Pfizer Investigational Site - St Louis
Maryland
- Pfizer Investigational Site - Baltimore
Pennsylvania
- Pfizer Investigational Site - Pittsburgh
Virginia
- Pfizer Investigational Site - Charlottesville
Other
- Pfizer Investigational Site - Orbassano (Torino)
Barcelona
- Pfizer Investigational Site - Badalona
BARCELONA
- Pfizer Investigational Site - Barcelona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00092001
The ClinicalTrials.gov registry entry for NCT00092001 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (66% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which Sunitinib is the first listed.
NCT00092001 reports 14 study locations spanning 8 distinct geographic areas - top geographies include North Carolina, Missouri, Maryland.
Frequently Asked Questions
What is clinical trial NCT00092001 about?
NCT00092001 is a clinical study titled "Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer". The purpose of this study is to test whether SU011248 has activity and is safe in patients with metastatic non-small cell lung cancer (NSCLC) who have failed a platinum-containing regimen and docetaxel.
What is the current status of trial NCT00092001?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2005-01. Estimated completion is 2007-03.
What conditions does trial NCT00092001 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT00092001?
The interventions under investigation include: Sunitinib (DRUG).
Who is sponsoring clinical trial NCT00092001?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00092001 being conducted?
This trial has 14 study locations across Maryland, Missouri, North Carolina, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
RECRUITING · Phase 2
-
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
RECRUITING · Phase 2
-
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
RECRUITING · Phase 2
-
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
RECRUITING · Phase 2
-
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.